Medical device regulatory readiness in Brazil (ANVISA)

Regulator: Agência Nacional de Vigilância Sanitária (ANVISA) oversees medical devices across premarket, manufacturing, importation, distribution, and post-market surveillance (tecnovigilância). Legal basis draws from Law No. 9.782/1999 (establishes ANVISA) and subsequent sectoral RDCs (Resoluções da Diretoria Colegiada). Key instruments (last major revisions): - RDC 751/2022: Core framework for classification, essential safety and performance requirements (ESPR), documentation, and approval pathways; supersedes RDC 185/2001 for devices (non-IVD). Annexes adopt GHTF-based rules and define the technical dossier structure. - RDC 665/2022: Good Manufacturing Practices (GMP/CBPF) procedures aligned to ISO 13485; enables use of MDSAP certificates as evidence for granting/maintaining Brazilian GMP (CBPF), with ANVISA discretion for inspections. - INMETRO Ordinances and conformity programs: Mandatory certification for specified product families (e.g., electromedical) to ABNT NBR IEC 60601 series via OCPs (Organismos de Certificação de Produto) accredited by Inmetro. - RDC 431/2020: Instructions for Use (IFU) and labeling, including provisions for electronic IFU (e-IFU) in defined circumstances. - Tecnovigilância framework: RDC 67/2009 and ANVISA guidance detail adverse event reporting (via Notivisa), field actions, and complaint handling. Other operational systems: Peticionamento eletrônico through Portal Solicita/Datavisa for submissions and tracking. Foreign manufacturers must operate via a Brazilian Registration Holder (BRH), a local legal entity with AFE (Autorização de Funcionamento de Empresa) authorization.

Brazil adopts a risk-based GHTF-style classification under RDC 751/2022: Class I (low), Class II (moderate), Class III (high), and Class IV (highest). Classification rules in Annex I consider intended use, contact duration and invasiveness, energy source, and whether the device sustains/supports life. Key drivers: - Invasiveness and duration (transient, short-term, long-term) - Active vs non-active and whether it administers/withdraws energy or substances - Implantability and life-support/life-sustaining claims - Use with medicinal products or blood/fluids - Sterility, measuring function, and reusability aspects Classification dictates the pathway: generally Cadastro for Class I and II, and Registro for Class III and IV. Certain special categories (e.g., electromedical, sterile, measuring) may impose additional testing and certification (e.g., INMETRO) regardless of the base class. Borderline and accessory determinations follow intended purpose statements; ANVISA may be petitioned for clarification when classification is ambiguous. Your classification also drives expectations for clinical evidence depth, technovigilância controls, and labeling particulars (e.g., serial/UDI readiness). Maintain a defensible rationale that maps each applicable rule to your risk outcome.

Pathways under RDC 751/2022: - Cadastro (Class I–II): Simplified route. Class I is typically notified with immediate grant upon complete electronic filing; Class II undergoes documentary review. Both require a technical dossier maintained by the BRH/manufacturer, available to ANVISA upon request. - Registro (Class III–IV): Full scientific-technical review. Requires comprehensive dossier, including clinical evidence where applicable. Core dossier content for both (depth increases for Registro): - Administrative: BRH authorization (AFE, CNPJ), powers of attorney for foreign manufacturers, applicant/manufacturer details, manufacturing sites, and fee proof. - Device description and intended use; variants/accessories; materials; sterilization and shelf-life (ISO 11135/11137/17665 as applicable); biocompatibility (ABNT NBR ISO 10993 series); electrical safety/EMC (ABNT NBR IEC 60601-1/-1-2) or relevant standards; software lifecycle for SaMD/SiMD (IEC 62304; see /glossary/iec-62304); usability (IEC 62366) when applicable. - Conformity to Essential Safety and Performance Requirements (ESPR) checklist per RDC 751/2022. - Risk management (ISO 14971) and benefit-risk summary. - Clinical evaluation/clinical investigation data for novel/high-risk technologies (Registro), aligned to GHTF/IMDRF principles; foreign clinical data are acceptable if applicable to the Brazilian population and context. - INMETRO: For electromedical and other designated products, provide valid Inmetro OCP certification and test reports to ABNT NBR standards before approval and commercialization. - GMP/CBPF: Evidence per RDC 665/2022—ANVISA-issued CBPF certificate or MDSAP certificate accepted to grant/maintain CBPF; ANVISA may still inspect. Submission mechanics: Peticionamento eletrônico via Portal Solicita.

RDC 665/2022 updates Brazil’s GMP (CBPF) program to align closely with ISO 13485 and the MDSAP audit model. Manufacturers must demonstrate an effective QMS covering design/development, production, servicing, purchasing, traceability (where applicable), complaint handling, corrective/preventive actions, and post-market surveillance. Key points: - MDSAP acceptance: ANVISA accepts valid MDSAP certificates issued by recognized Auditing Organizations as evidence to grant or maintain CBPF for the certified scope. ANVISA retains discretion to conduct inspections. - Scope accuracy: Ensure all manufacturing sites (including sterilizers, critical suppliers, and software development sites for SaMD) are within the certified scope. Misaligned scopes trigger deficiencies. - BRH integration: The BRH must maintain procedures for distribution, vigilance, and recalls; interfaces with the foreign manufacturer’s QMS should be defined contractually and procedurally. - Records: Maintain DMR/DHR, validation (processes, software used in production/quality), equipment calibration, environmental controls, and training records in Portuguese or with certified translations for inspection. - MDSAP modules mapping: Leverage the MDSAP Brazil country-specific requirements (including tecnovigilância and labeling controls) to prepare for CBPF and inspections without surprises.

Labeling and IFU: RDC 431/2020 sets requirements for labeling and instructions for use. Content must be in Brazilian Portuguese, including device name/model, manufacturer and BRH (name, address, CNPJ), ANVISA approval number (Cadastro or Registro), lot/serial number, manufacturing/expiry dates (where applicable), storage conditions, single-use/sterility status, warnings/precautions, and importer details for imported products. Electromedical products must bear the INMETRO conformity mark once certified. E‑IFU is permitted for certain professional-use devices under defined risk controls; lay-use and many implantables still require paper IFU. UDI: ANVISA is developing a UDI framework aligned with IMDRF principles (device identifier on label and submission of core data to an ANVISA UDI database). While final RDC and timelines are pending, manufacturers should prepare to encode a Basic UDI-DI-like identifier and production identifiers, maintain master data, and ensure label/packaging space and data governance are UDI-ready. Translations: All end-user content must be in Portuguese; technical files may be in English but ANVISA can request Portuguese translations of critical sections. Consistency between IFU, labeling, and the dossier is scrutinized.

Brazil’s tecnovigilância system obligates manufacturers/BRHs to monitor device performance, collect/analyze complaints, and report adverse events and field actions to ANVISA via Notivisa. Core expectations: - Complaint handling: Maintain processes to log, investigate, trend, and close complaints; determine reportability per Brazilian criteria. - Reporting timelines: Serious adverse events (death or serious deterioration in health) typically require initial notification within 10 calendar days; other reportable incidents within 30 calendar days. Provide follow-up and a final investigation report when available; ANVISA may set case-specific deadlines. - Field Safety Corrective Actions (Ações de Campo): Notify ANVISA promptly, implement corrections/recalls, and communicate to users/distributors in Portuguese; submit effectiveness checks and closure reports. - PMS plans: For higher-risk or novel devices, maintain proactive PMS methods (surveys, PMCF-like activities, literature review) supporting ongoing benefit–risk. - BRH role: The BRH is the local focal point for Notivisa submissions, coordination with healthcare services, and stock recovery. Keep distribution traceability sufficient to execute targeted field actions. Deficiency patterns include late reporting, incomplete root cause/CAPA, and inconsistent labeling claims vs IFU/usability evidence.

Days 0–30: Strategy and classification - Appoint/select a Brazilian Registration Holder (BRH) with AFE; execute technical and vigilance responsibilities in the contract. - Classify the device under RDC 751/2022; confirm pathway (Cadastro vs Registro); identify if INMETRO applies (electromedical, etc.). - Gap assess QMS to RDC 665/2022 and MDSAP; confirm site scopes; plan to leverage MDSAP for CBPF. - Start Portuguese labeling/IFU authoring; define claims consistent with dossier. Days 31–60: Evidence assembly and certification kickoff - Compile ESPR checklist; finalize risk management (ISO 14971) and V&V matrices; confirm biocompatibility/sterilization evidence. - If applicable, engage an Inmetro-accredited OCP; submit product samples and CB reports; schedule any factory audit; typical cycle 6–10 weeks. - For SaMD/active devices, finalize IEC 62304 and 60601-1/-1-2 evidence. - Build the Brazil technical dossier (Cadastro or Registro depth) and translation plan; load administrative documents (BRH AFE/CNPJ, powers of attorney). Days 61–90: Submission and GMP alignment - File peticionamento eletrônico via Portal Solicita; include INMETRO certificate or furnish proof of ongoing certification if ANVISA allows staged submission (verify case-by-case). - If needed, request CBPF based on MDSAP; respond to any ANVISA scheduling/data requests. - Stand up tecnovigilância SOPs and Notivisa access for the BRH; train distribution partners. Days 91–180: Review, responses, and launch prep - Manage ANVISA exigências within deadlines; maintain a single-source dossier for updates. - Complete INMETRO and affix the conformity mark; finalize Portuguese labeling with ANVISA/Registro number once granted. - Validate distribution and recall traceability; rehearse field action communication temp.